Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib malate it works in treating
patients with previously untreated metastatic kidney cancer.